Canada markets closed
  • S&P/TSX

    20,621.39
    -436.79 (-2.07%)
     
  • S&P 500

    4,397.94
    -84.79 (-1.89%)
     
  • DOW

    34,265.37
    -450.02 (-1.30%)
     
  • CAD/USD

    0.7947
    -0.0052 (-0.65%)
     
  • CRUDE OIL

    84.83
    -0.72 (-0.84%)
     
  • BTC-CAD

    44,041.24
    -1,786.03 (-3.90%)
     
  • CMC Crypto 200

    870.86
    +628.18 (+258.85%)
     
  • GOLD FUTURES

    1,836.10
    -6.50 (-0.35%)
     
  • RUSSELL 2000

    1,987.92
    -36.12 (-1.78%)
     
  • 10-Yr Bond

    1.7470
    -0.0860 (-4.69%)
     
  • NASDAQ

    13,768.92
    -385.10 (-2.72%)
     
  • VOLATILITY

    28.85
    +3.26 (+12.74%)
     
  • FTSE

    7,494.13
    -90.88 (-1.20%)
     
  • NIKKEI 225

    27,522.26
    -250.67 (-0.90%)
     
  • CAD/EUR

    0.7001
    -0.0066 (-0.93%)
     

Global Hypoglycemia Drug Forecast and Market Analysis Report 2021-2030: Focus on Diabetic Hypoglycemia, and Post-bariatric Surgery Hypoglycemia (PBH) - ResearchAndMarkets.com

·5 min read

DUBLIN, December 06, 2021--(BUSINESS WIRE)--The "Hypoglycemia - Global Drug Forecast and Market Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.

This report will focus on diabetic hypoglycemia, and post-bariatric surgery hypoglycemia (PBH). There is currently no approved treatment for PBH.

The therapeutic market for hypoglycemia within the 7MM will grow from $423.5M in 2020 at a compound annual growth rate (CAGR) of 4.8% to $657.1M by 2030. In particular, the US market will contribute the most to the hypoglycemia market's growth, contributing $399.8M sales in 2020 (94% of the hypoglycemia market) and $577.1M in 2030 (85.5% of the hypoglycemia market)

The launch of the novel formulations of glucaon therapeutics will be the main drivers of growth over the forecast period, with the first liquid-stable glugaons expected to launch during the forecast period in addition to increased uptake of nasal glucagon, Baqsimi. Other major drivers for the hypoglycemia market include the increased T1D diagnosed prevalence, and the uptake of novel glucagon formulations will drive therapy usage over hospital treatment.

Based on the epidemiological analysis by The publisher, the diagnosed incident cases of severe hypoglycemia attributed to T1D will grow by 4.7% over the next decade, from 17,359 cases in 2020 to 18,180 cases in 2030, at an Annual Growth Rate (AGR) of 0.5% per year in the seven major pharmaceutical markets (7MM) covered in this report, the US, 5EU (France, Germany, Italy, Spain, and UK), and Japan.

The diagnosed incident cases of severe hypoglycemia attributed to T2D will grow by 1.4% over the next decade, from 173,085 cases in 2020 to 175,530 cases in 2030 at an AGR of 0.1% in the 7MM. The diagnosed incident cases of PBH will grow by 18.7% over the next decade, from 50,227 cases in 2020 to 59,627 cases in 2030 at an AGR of 1.7% in the 7MM.

The consensus among interviewed physicians regarding the current treatment landscape of hypoglycemia is that there are sufficient treatments to address severe hypoglycemia, and there are few unmet needs for hypoglycemia that can be addressed therapeutically. Key Opinion Leaders (KOLs) interviewed by

The primary unmet need is that there are no adequate treatments for non-diabetic hypoglycemia. Other unmet needs include the lack of affordable treatments, the lack of convenient treatments, and the prevalence of hypoglycemia unawareness.

The research suggests that the future level of attainment of these unmet needs will be medium-high, and there is not much of an of opportunity for drug developers to enter the severe hypoglycemia market, but there is opportunity to address the non-diabetic hypoglycemia market.

Key Highlights

  • The diagnosed incidence of hypoglycemia and severe hypoglycemia is expected to increase over the 10-year forecast period due to the increasing prevalence of both T1D and T2D.

  • The increased uptake of Baqsimi and liquid-stable glucagons will increase the number of patients who can treat their hypoglycemia outside of a hospital setting and improve overall quality of life. These drugs are expected to have a high annual cost of therapy (ACOT), a factor that will contribute to notable profitability.

  • The increasing trend of glucose monitoring in the treatment and management of insulin-dependent diabetic patients will impact the therapeutics that find success in the market. Increased monitoring will allow patients to catch hypoglycemia before it becomes severe. For T1D, the drive toward closed-loop pump systems, like an artificial pancreas, provides an opportunity for dual-hormonal pumps to use glucagon to actively manage hypoglycemia.

  • Severe hypoglycemia is adequately treated, and there is little room for new entrants. The launch of the first liquid-stable and inhalable glucagons has made rescue treatment easier. The most recognizable needs the larger market must address are that insulins are still causing hypoglycemia and non-diabetic hypoglycemia need targeted treatments.

Key Topics Covered:

1 Hypoglycemia: Executive Summary

1.1 The Hypoglycemia Market Will Grow to 675.1M by 2030

1.2 New Hypoglycemia Players Are Focusing on Increasing Ease-of-Use and Integration with Technologies

1.3 There Are Few Unmet Needs for Hypoglycemia That Can Be Addressed Therapeutically

1.4 Pipeline Therapies and Device Integration Could Greatly Impact the Incidence of Severe Events

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.3.1 Diagnosed Incidence of Hypoglycemia Attributed to Type 1 Diabetes

4.3.2 Diagnosed Incidence of Hypoglycemia Attributed to Type 2 Diabetes

4.4 7MM Forecast Methodology

4.5 Epidemiological Forecast for Hypoglycemia (2020-2030)

4.6 Discussion

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 Patient Hypoglycemia Self-Management Practices Across the 7MM

5.3 Severe Hypoglycemia Treatment Practices Across the 7MM

5.3.1 Hospitalization Across the 7MM Markets

5.4 Non-diabetic Hypoglycemia Management Across the 7MM

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Treatments for Non-diabetic Hypoglycemia

7.3 Severe Hypoglycemia Prevention

7.4 Ease of Glucagon Administration

7.5 Glucagon Cost

7.6 Hypoglycemia Awareness

8 R&D Strategies

8.1 Overview

8.2 Clinical Trials Design

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

11 Current and Future Players

12 Market Outlook

13 Appendix

Companies Mentioned

  • Novo Nordisk

  • Eli Lilly

  • Zealand Pharma

  • Xeris Pharmaceuticals

  • Eiger Biopharmaceuticals

  • Fresenius Kabi

  • Amphastar Pharmaceuticals

  • Fuji Pharma

  • Kaigen Pharma

For more information about this report visit https://www.researchandmarkets.com/r/rtnhn

View source version on businesswire.com: https://www.businesswire.com/news/home/20211206005609/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting